BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31916463)

  • 1. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
    Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
    Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
    Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
    Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
    Miano ST; Francini E; Petrioli R; Francini G
    Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dedifferentiated liposarcoma: when eribulin can make the difference.
    Sbrana A; Paolieri F; Bloise F; Manacorda S; Nuzzo A; Sammarco E; Galli L; Falcone A
    Future Oncol; 2020 Jan; 16(1s):21-24. PubMed ID: 31872768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.
    Aliberti S; Miano S; Tolomeo F; Merlini A; Aglietta M; Grignani G
    Future Oncol; 2020 Jan; 16(1s):15-19. PubMed ID: 31916842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin in advanced liposarcoma and leiomyosarcoma.
    Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin long-term response and rechallenge: report of two clinical cases.
    Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
    Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
    Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
    Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term eribulin treatment in patients with a single kidney and retroperitoneal liposarcoma.
    Tober N; Gentile M; Iodice G
    Future Oncol; 2020 Jan; 16(1s):5-8. PubMed ID: 31872769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
    Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
    Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
    Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
    Wozniak A; Boeckx B; Modave E; Weaver A; Lambrechts D; Littlefield BA; Schöffski P
    Clin Cancer Res; 2021 Jun; 27(11):3106-3115. PubMed ID: 33795257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
    Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
    Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
    Caputo R; Cianniello D; De Laurentiis M
    Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.